1. Home
  2. AKBA vs USPH Comparison

AKBA vs USPH Comparison

Compare AKBA & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • USPH
  • Stock Information
  • Founded
  • AKBA 2007
  • USPH 1990
  • Country
  • AKBA United States
  • USPH United States
  • Employees
  • AKBA N/A
  • USPH N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • USPH Medical/Nursing Services
  • Sector
  • AKBA Health Care
  • USPH Health Care
  • Exchange
  • AKBA Nasdaq
  • USPH Nasdaq
  • Market Cap
  • AKBA 958.6M
  • USPH 1.1B
  • IPO Year
  • AKBA 2014
  • USPH 1992
  • Fundamental
  • Price
  • AKBA $3.66
  • USPH $75.03
  • Analyst Decision
  • AKBA Strong Buy
  • USPH Strong Buy
  • Analyst Count
  • AKBA 5
  • USPH 4
  • Target Price
  • AKBA $6.90
  • USPH $109.00
  • AVG Volume (30 Days)
  • AKBA 3.2M
  • USPH 188.2K
  • Earning Date
  • AKBA 08-07-2025
  • USPH 08-06-2025
  • Dividend Yield
  • AKBA N/A
  • USPH 2.38%
  • EPS Growth
  • AKBA N/A
  • USPH 81.25
  • EPS
  • AKBA N/A
  • USPH 2.17
  • Revenue
  • AKBA $184,909,000.00
  • USPH $692,325,000.00
  • Revenue This Year
  • AKBA $26.88
  • USPH $16.68
  • Revenue Next Year
  • AKBA $44.34
  • USPH $6.05
  • P/E Ratio
  • AKBA N/A
  • USPH $34.79
  • Revenue Growth
  • AKBA N/A
  • USPH 14.30
  • 52 Week Low
  • AKBA $1.07
  • USPH $62.77
  • 52 Week High
  • AKBA $4.08
  • USPH $101.20
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 48.61
  • USPH 47.13
  • Support Level
  • AKBA $3.47
  • USPH $72.97
  • Resistance Level
  • AKBA $4.04
  • USPH $76.69
  • Average True Range (ATR)
  • AKBA 0.17
  • USPH 1.78
  • MACD
  • AKBA -0.06
  • USPH 0.01
  • Stochastic Oscillator
  • AKBA 31.20
  • USPH 62.97

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About USPH U.S. Physical Therapy Inc.

US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.

Share on Social Networks: